Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy

British Journal of Dermatology

Volumn 166, Issue 3, 2012, Pages 511-517

  Feldman, R J ^a   Christen, W G ^b   Ahmed, A R ^a  

^a Center for Blistering Diseases   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB;

ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; IMMUNOTHERAPY; LYMPHOCYTE SUBPOPULATION; MALE; MULTIPLE CYCLE TREATMENT; PEMPHIGUS VULGARIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; DERMATOLOGIC AGENTS; DESMOGLEIN 1; DESMOGLEIN 3; FEMALE; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PEMPHIGUS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES;

EID: 84857626509     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10658.x     Document Type: Article

References (31)

1. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159: 2010-17. (Pubitemid 127484192)
2. Bystryn JC, Steinman NM,. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-12.
3. Ahmed AR, Dahl MV,. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139: 1051-9. (Pubitemid 36994832)
4. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR, Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-9. (Pubitemid 44631360)
5. Feldman R, Ahmed AR,. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol 2011; 7: 529-41.
6. Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128: 2859-69.
7. Belloni-Fortina A, Faggion D, Pigozzi B, et al. Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up. Clin Dev Immunol 2009; 2009: 187864.
8. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.
9. Foster CS, Chang PY, Ahmed AR,. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117: 861-9.
10. Popa C, Leandro MJ, Cambridge G, Edwards JC,. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 626-30. (Pubitemid 46523308)
11. Faurschou A, Gniadecki R,. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris. Int J Dermatol 2008; 47: 292-4. (Pubitemid 351266854)
12. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52. (Pubitemid 47236279)
13. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 2580-9. (Pubitemid 39062719)
14. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
15. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-43.
16. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81. (Pubitemid 38758544)
17. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20. (Pubitemid 43228639)
18. Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S,. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med 2011; 40: 616-20.
19. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377-86. (Pubitemid 44204997)
20. Sanz I, Anolik JH, Looney RJ,. B cell depletion therapy in autoimmune diseases. Front Biosci 2007; 12: 2546-67.
21. Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 62-74. (Pubitemid 46026695)
22. Furst DE,. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum 2009; 39: 18-29.
23. Harman KE, Gratian MJ, Bhogal BS, et al. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 2000; 143: 343-8. (Pubitemid 30650403)
24. Bhol K, Mohimen A, Ahmed AR,. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994; 189 (Suppl. 1): 85-9. (Pubitemid 24141436)
25. Bhol K, Natarajan K, Nagarwalla N, et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 1995; 92: 5239-43.
26. Amagai M, Ahmed AR, Kitajima Y, et al. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just 'witnesses of disease'? Exp Dermatol 2006; 15: 815-31.
27. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.
28. Ahmed AR,. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 679-90. (Pubitemid 33032563)
29. Baum S, Scope A, Barzilai A, et al. The role of IVIG treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006; 20: 548-52.
30. Herbst A, Bystryn JC,. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42: 422-7. (Pubitemid 30470348)
31. Kavusi S, Daneshpazhooh M, Farahani F, et al. Outcome of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2008; 22: 580-4. (Pubitemid 351541053)